{"organizations": [], "uuid": "86810e7b5dd7fc0d5fc6751c56fbfe3c764fe235", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180419.html", "section_title": "Archive News &amp; Video for Thursday, 19 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-tocagen-and-apollobio-enter-licens/brief-tocagen-and-apollobio-enter-license-agreement-to-develop-toca-511-toca-fc-in-greater-china-idUSFWN1RW0L5", "country": "US", "domain_rank": 408, "title": "BRIEF-Tocagen And ApolloBio Enter License Agreement To Develop Toca 511 & Toca FC In Greater China", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-19T20:07:00.000+03:00", "replies_count": 0, "uuid": "86810e7b5dd7fc0d5fc6751c56fbfe3c764fe235"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-tocagen-and-apollobio-enter-licens/brief-tocagen-and-apollobio-enter-license-agreement-to-develop-toca-511-toca-fc-in-greater-china-idUSFWN1RW0L5", "ord_in_thread": 0, "title": "BRIEF-Tocagen And ApolloBio Enter License Agreement To Develop Toca 511 & Toca FC In Greater China", "locations": [], "entities": {"persons": [{"name": "tocagen", "sentiment": "none"}], "locations": [{"name": "greater china", "sentiment": "none"}, {"name": "china", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "develop toca 511 & toca", "sentiment": "negative"}, {"name": "tocagen inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 19 (Reuters) - Tocagen Inc:\n* TOCAGEN AND APOLLOBIO ENTER LICENSE AGREEMENT TO DEVELOP AND COMMERCIALIZE TOCA 511 & TOCA FC IN THE GREATER CHINA REGION\n* TOCAGEN INC - TOCAGEN ELIGIBLE TO RECEIVE UP TO $127 MILLION IN UPFRONT PAYMENT, DEVELOPMENT AND COMMERCIAL MILESTONES\n* TOCAGEN - ELIGIBLE TO RECEIVE ADDITIONAL DOUBLE-DIGIT TIERED SALES ROYALTIES UPFRONT AND NEAR-TERM DEVELOPMENT MILESTONES PAYMENTS TOTAL UP TO $20 MILLION\n* TOCAGEN INC - WILL BE ELIGIBLE FOR ADDITIONAL FUTURE PAYMENTS TOTALING UP TO $111 MILLION UPON MEETING CERTAIN DEVELOPMENT AND COMMERCIAL MILESTONES\n* TOCAGEN INC - WILL BE RESPONSIBLE FOR ALL DEVELOPMENT AND COMMERCIALIZATION COSTS IN LICENSED TERRITORY\n* TOCAGEN INC - LICENSE GRANT TO APOLLOBIO IS EXPECTED TO BECOME EFFECTIVE IN Q2 OF 2018 Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-19T20:07:00.000+03:00", "crawled": "2018-04-20T11:31:59.011+03:00", "highlightTitle": ""}